LEXINGTON, Mass., Feb. 16, 2017 /PRNewswire/ -- iSpecimen®, the marketplace for human biospecimen collections, today announced that its founder and chief executive officer, Christopher Ianelli, MD, PhD, will join a panel of medical innovators next week in presenting emerging technologies for molecular medicine. This keynote panel will take place on Wednesday, February 22 as part of the Cambridge HealthTech Institute's Molecular Med Tri-Con event in San Francisco.
Molecular Med Tri-Con attracts more than 3,500 drug discovery and development professionals from more than 40 countries focused on molecular medicine. "Emerging Technologies and Industry Perspectives" will be held between 8:00-10:00am PST at the Moscone North Convention Center.
As part of the keynote session, Dr. Ianelli will discuss an online marketplace model for human biospecimen procurement, which will be essential tor driving precision research, a necessary precursor to precision medicine. Due to the hot pursuit of precision medicine for all, scientists more than ever need a high-quality, diverse, and annotated supply of specimens that are selected just as precisely as the medicine we pursue. In his talk, Dr. Ianelli will describe how advances in technology and standardization of medical record data can now enable an online marketplace where researchers can easily search for precise specimens and patients they need for their studies, bringing efficiencies to biospecimen procurement.
Dr. Ianelli is one of eight speakers on the panel who will describe a clinical problem and a tech-driven innovation. The session moderator and other panelists include: Keith F. Batchelder, M.D., CEO and Founder, Genomic Healthcare Strategies; Christopher Mueller, Ph.D., President & CTO, Lab7 Systems; Dick Rubin, Vice President, Sales & Marketing, Accel Biotech LLC; Joe Ferrara, President, Boston Healthcare; Rudi Pauwels, Ph.D., Founder & CEO, Biocartis; Russell Garlick, Ph.D., CSO, SeraCare Life Sciences; Sean Ferree, Ph.D., Vice President, Diagnostic Development, NanoString Technologies; and Farideh Bischoff, Ph.D., Chief Clinical Development Officer, North America Menarini Silicon Biosystems.
In addition to iSpecimen's presence on the keynote panel, the company can also be found during the conference at booth number 217.
iSpecimen is the marketplace for human biospecimen collections, providing researchers with the specimens they need from the patients they want. Headquartered in Lexington, Massachusetts, the privately held company uses proprietary cloud-based technology to match qualifying samples and associated data from its diverse network of hospitals, labs, biobanks, blood centers, and other clinical organizations to biomedical researchers' specimen requests. iSpecimen sources biofluids, solid tissue, and primary cells, offering clinical remnants, banked samples, and samples collected prospectively for research. Scientists gain easy access to the high-quality samples they need for their research. Partner sites gain an opportunity to further contribute to biomedical discovery as well as their bottom line. And ultimately, healthcare advances for all. For more information about iSpecimen, please visit www.ispecimen.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ispecimen-founder--ceo-to-present-on-emerging-technology-keynote-panel-at-molecular-med-tri-con-300409268.html